All content on this website is provided for educational and research purposes only. It does not constitute medical advice or treatment. This article discusses biological mechanisms also observed in laboratory and preclinical research models, so no clinical efficacy or safety for human use is implied. The substances discussed, which are not registered medicines, are not intended for use in humans or animals.

CagriSema

CagriSema is an investigational combination therapy being studied for the treatment of obesity and metabolic disorders, including type 2 diabetes. It combines two biologically active compounds that influence appetite regulation and energy metabolism.

CagriSema consists of Semaglutide and Cagrilintide. The therapy is being developed by Novo Nordisk.

By combining these two mechanisms, CagriSema aims to influence multiple hormonal pathways involved in appetite, satiety, and metabolic regulation.

Because of its multi-hormonal approach, the therapy has attracted significant interest in clinical research related to weight management and metabolic disease. CagriSema is currently considered an investigational therapy and has not yet received full regulatory approval.

How CagriSema works

CagriSema combines two hormones that act on different biological pathways involved in appetite regulation and metabolic control.

Semaglutide acts as a GLP-1 receptor agonist, which may:

  • increase satiety signals in the brain

  • slow gastric emptying

  • improve glucose regulation

Cagrilintide acts as an amylin receptor agonist, which may:

  • enhance satiety and appetite control

  • reduce food intake

  • influence signaling pathways involved in energy balance

Together, these mechanisms may produce complementary effects on appetite suppression and metabolic regulation, which is why combination therapies such as CagriSema are being investigated for long-term weight management.

CagriSema - approximate diagram of the molecule

Clinical trials and evidence

CagriSema is currently being evaluated in clinical trials involving people with obesity and type 2 diabetes. Research has examined:

  • weight reduction in individuals with obesity or overweight

  • improvements in glycemic control

  • changes in metabolic markers associated with energy balance and appetite regulation

Early clinical trials have reported substantial weight loss among participants receiving the combination therapy compared with placebo or individual components alone.

These findings have supported further development of CagriSema in large phase III clinical trials designed to evaluate long-term safety and effectiveness.

However, as with other investigational therapies, additional research is required before regulatory approval can be considered.

Possible side effects of CagriSema:

Because CagriSema influences gastrointestinal and metabolic pathways, the most commonly reported side effects are gastrointestinal symptoms, similar to those observed with GLP-1–based therapies. Reported side effects may include:

  • nausea

  • vomiting

  • diarrhea

  • decreased appetite

  • abdominal discomfort

These effects are often dose-dependent and may occur more frequently during the initial stages of treatment.

The complete safety profile of CagriSema continues to be evaluated in ongoing clinical trials.

References:

– Efficacy and safety of co‑administered once‑weekly cagrilintide 2.4 mg with once‑weekly semaglutide 2.4 mg in type 2 diabetes, Frias et al., 2023 – The Lancet, https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01163-7/abstract

– Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1), Garvey et al., 2025 – New England Journal of Medicine, https://mediacenteratypon.nejmgroup-production.org/NEJMoa2502081.pdf

– Cagrilintide–Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes, Davies et al., 2025 – NEJM, https://www.nejm.org/doi/suppl/10.1056/NEJMoa2502082/suppl_file/nejmoa2502082_protocol.pdf

CagriSema is an investigational combination therapy currently undergoing clinical trials and has not yet been widely approved as a prescription medication by major regulatory authorities. Scientific research involving such compounds should be conducted with appropriate safety precautions and in accordance with applicable laws and regulations in the relevant country.

The purpose of this website is to provide clear, evidence-based information about biologically active compounds often discussed in research, metabolic health, and biohacking communities. The information presented here is educational and should not be considered medical advice.

CagriSema
Action: Weight loss | Category: GLP-1 combination
Experimental dosage: 0.25 mg (first 4 weeks), 0.5 mg (weeks 5-8), 1 mg (weeks 9-12), 1.7 mg (weeks 13-16), maximum dose 2.4 mg from week 17 (optional). | Frequency: every week | Timing: morning | Cycle on: Titrate every 4 weeks if well tolerated; reassess efficacy and tolerability every 12 weeks; do not escalate in case of significant adverse effects. — Route: subcutaneous (SC). Stop rules: hold and seek medical advice if moderate/severe adverse effects occur (e.g., escalating nausea/vomiting, dizziness, palpitations, significant blood pressure changes, severe injection‑site reactions, allergic symptoms) or if there is no clear ‘return‑to‑baseline’ window between doses. | Cycle off: -
Effectiveness: ■■■■▢ | Safety: ■■■■▢

Related peptides

Peptides from the same functional group:Dulaglutide, Exenatide, Liraglutide, Mazdutide, Retatrutide, Semaglutide

Our peptides database

5-Amino-1MQ | AICAR peptide | AOD9604 peptide | Arg-BPC-157 peptide | BPC-157 peptide | CagriSema | Cerebrolysin peptide | CJC-1295 NO DAC peptide | CJC-1295 with DAC peptide | Cortagen peptide | Dihexa peptide | DSIP peptide (Delta Sleep-Inducing Peptide) | Dulaglutide peptide | Epithalon peptide | Exenatide peptide | Follistatin 315 peptide | Follistatin 344 peptide | FOXO4-DRI peptide | GHK-Cu peptide | GHRP-2 peptide | GHRP-6 peptide | Hexarelin peptide | HGH Fragment 176-191 | Humanin peptide | IGF-1 LR3 peptide | Ipamorelin CJC-1295 NO DAC | Ipamorelin peptide | Kisspeptin peptide | KPV peptide | L-Carnitine | Liraglutide peptide | Livagen peptide | LL-37 peptide | Matrixyl peptide | Mazdutide peptide | Melanotan II peptide | Melanotan peptide | MGF peptide (Mechano Growth Factor peptide) | MOD GRF 1-29 | MOTS-C peptide | NAD+ coenzime (Nicotinamide Adenine Dinucleotide) | Oxytocin peptide | P21 peptide | PEG-MGF peptide | Pinealon peptide | PT-141 peptide (Bremelanotide) | PTD-DBM peptide | Retatrutide | Selank peptide | Semaglutide | Semax peptide | Sermorelin peptide | SHLP-2 peptide | SHLP-6 peptide | Somatropin peptide | SS-31 peptide (Elamipretide) | TB-500 peptide | Tesamorelin peptide | Thymosin Alpha 1 peptide | Thymosin beta 4 peptide | Thymosin β10 peptide | Thymulin peptide | Tirzepatide | Vilon peptide
Tagged